Nuclear Medicine imaging and therapy : centre of excellence

01/02/2025

We are pleased to present our recently published original article emphasizing the immunomodulatory potential of [177Lu]Lu-PSMA Radioligand Therapy increasing the presentation of neoantigens and tumor-associated antigens, leading to an in situ “vaccination” effect. In our dual centre study of 36 patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-PSMA radioligand therapy (PRLT), persistent therapeutic responses were observed, including clinical improvement, biochemical response (PSA levels), and molecular imaging responses. These findings suggest that radioligand therapy’s immunomodulatory effects contribute to its enhanced therapeutic potential beyond the effects of radiation alone. These results, along with other studies investigating immunomodulatory effects of Radioligand Therapy, may help optimizing current treatment protocols and promoting the earlier use of radioligand therapies in oncology.

Thank you to this super-team of colleagues! Elisabetta Perrone, Lucille Heslop, Kriti Ghai, Trisha Govender, Dr Nisaar Korowlay, Tanay Parkar, Ralph Wirtz, Richard P. Baum

ICPO Foundation-International Centers for Precision Oncology Umhlanga Molecular Imaging and Therapy Loveworld Medical Centre Nuclear Medicine Department LMC Hibiscus Hospital

Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PRLT) with Lutetium-177 ([177Lu]Lu-PSMA) is a safe and effective treatment for metastatic castration-resistant prostate cancer (mCRPC). The aim of our study was to evaluate clinical variables of patients with extreme...

10/01/2025

We present an 80-year-old woman with cholestatic liver disease. Ultrasound, CT, and MR cholangiopancreatography showed no substantial findings. The patient was referred for a hepatobiliary scan to examine the physiological pathway of bilirubin and to determine for any level of obstruction. The findings on the hepatobiliary scan suggested intrinsic pathology affecting the entire biliary tree, and histology was recommended. Histology confirmed primary sclerosing cholangitis (PSC). Although hepatobiliary scintigraphy in biliary stasis is well-known and well-published, hepatobiliary scintigraphy in PSC in adults is not well-documented. The hepatobiliary scintigraphy provided the primary and definitive imaging technique in directing the management and diagnosis of PSC in our patient.

; ; ; ; ;

ndings on the hepatobiliary scan suggested intrinsic pathology affecting the entire biliary tree, and histology was recommended. Histology confirmed primary sclerosing cholangitis (PSC). Although hepatobiliary scintigraphy in biliary stasis is well-known and well-published, hepatobiliary scintigraph...

10/01/2025

We are happy to inform you that a new EANM/SNMMI Guideline was published in EJNNMI last month! Many thanks to all the volunteers who made it possible, as well as to Society of Nuclear Medicine and Molecular Imaging and ESTRO for their collaboration: EANM/SNMMI practice guideline for [18F]FDG PET/CT external beam radiotherapy treatment planning in uterine cervical cancer v1.0
👉You can read the full article here (open access): https://link.springer.com/article/10.1007/s00259-020-05112-2

10/01/2025

21/05/2024

https://ow.ly/2rpP50REnMX

21/05/2024

Hematological and Renal Safety of 177Lu-PSMA-617 Radioligand Therapy in patients with Metastatic Castration Resistant Prostate Carcinoma – A Single Center Experience in Pakistan